Rheumatoid Arthritis (RA) Pipeline Insight Report 2020 Featuring 10 Key Players & 12 Products - ResearchAndMarkets.com

The "Rheumatoid Arthritis (RA) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Rheumatoid Arthritis - Pipeline Insight, 2020" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis Emerging Drugs

HB-adMSCs: Hope Biosciences

Hope Bio's core technology lies in stem cell culture and banking. Mesenchymal stem cells are isolated from approximately one tablespoon of fat tissue, purified, and cultured with Hope Bio's proprietary culture media, HB-101. HB-adMSCs are expanded to multiple passages and released at Passage 4 for therapeutic use. HB-adMSCs have already been used as a safe and effective treatment in a Phase I/IIa clinical trial for Rheumatoid Arthritis.

ABX464: Abivax

The Phase 2a study, ABX464-301, investigates the safety and tolerability of ABX464 in combination with methotrexate in patients with moderate-to-severe active Rheumatoid Arthritis. Patients enrolled in the study had an inadequate response to methotrexate or/and to one or more anti-tumor necrosis factor alpha (TNF?) therapies.

Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report.

Major Players in Rheumatoid Arthritis

There are approx. 50+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Gilead Sciences, Galapagos NV, Abivax, Viela Bio, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Oscotec, Yungjin Pharm. Co., Ltd., AbbVie, Aclaris Therapeutics, Inc., Navidea Biopharmaceuticals, Bristol-Myers Squibb, SynAct Pharma Aps etc.

Key Players

• Gilead Sciences
• Galapagos
• Abivax
• Viela Bio
• Jiangsu Alphamab Biopharmaceuticals Co.
• Oscotec, Yungjin Pharm.
• AbbVie, Aclaris Therapeutics
• Navidea Biopharmaceuticals
• Bristol-Myers Squibb
• SynAct Pharma Aps

Key Products

• HB-adMSCs
• FURESTEM-RA Inj
• Autologous adipose derived stem cells
• ABX464
• TJ003234
• Umbilical cord mesenchymal stem cells
• Ianalumab
• GCK
• hUC-MSC suspension
• VIB4920
• PF-06650833
• GB224

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1fi08q

View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005446/en/